Kroger Posts 12% EPS Gain in Fiscal Q2

Kroger reported strong operational performance in Q2 FY2025, with identical sales excluding fuel climbing 3.4% and non-GAAP EPS rising 11.8% year-over-year to $1.04, despite headline revenue remaining flat at $33.9 billion. The supermarket operator also saw adjusted FIFO operating profit increase 10.9% and gross margin expand to 22.5%, partly aided by the specialty pharmacy divestiture and cost controls. Reflecting this momentum, Kroger raised the lower end of its full-year FY2025 guidance for sales growth, operating profit, and EPS, while also increasing its quarterly dividend by 9.4%.

Analysis

Kroger's (KR) second-quarter fiscal 2025 results demonstrate robust underlying operational strength despite flat headline revenue of $33.9 billion. The key performance indicator, identical sales excluding fuel, accelerated significantly to 3.4% from 1.2% in the prior-year period, signaling strong consumer engagement and core business momentum. This top-line strength in the core grocery segment, coupled with effective cost management, drove an 11.8% year-over-year increase in non-GAAP earnings per share to $1.04 and a 10.9% rise in adjusted FIFO operating profit. Gross margin expanded by 40 basis points to 22.5%, though this was largely attributable to the one-time impact of the specialty pharmacy divestiture. Strategic initiatives are showing progress, with digital sales growing 16% and management actively optimizing its store portfolio. While net debt leverage increased to 1.63x, the company demonstrated confidence through a 9.4% dividend increase and a commitment to its buyback program. The decision to raise the lower end of its full-year guidance for sales, operating profit, and EPS reinforces a positive outlook for the remainder of fiscal 2025.

Key Decisions for Investors

• Investors should look past the flat headline revenue, which was distorted by a divestiture, and focus on the accelerating identical sales growth of 3.4% and the 11.8% EPS increase as superior indicators of core operational health.
• The upward revision to the low end of FY2025 guidance provides a stronger floor for earnings expectations, warranting a potential upward adjustment in valuation models for the company.
• While the 9.4% dividend hike and ongoing buybacks signal management confidence, it is prudent to monitor the increased net debt leverage of 1.63x to ensure it remains within the company's stated tolerance.
• Consider the long-term margin mix, as key growth drivers like the pharmacy segment and digital sales, whose profitability is undisclosed, may carry lower margins than the core business, potentially tempering future profit expansion.